Skip to main content
. 2024 Aug 28;15:7359. doi: 10.1038/s41467-024-50498-4

Fig. 8. The combination of DAC and TAK-243 is effective for primary AML samples.

Fig. 8

a Clinical information and genetic mutations of patient samples. AMMoL, acute myelomonocytic leukemia; AML-MRC, AML with myelodysplasia-related changes. b Synergistic effects between DAC and TAK-243 in patients’ samples at various combinations of concentrations. Synergy was calculated using the SynergyFinder 3.0, and BLISS was used to denote scores. Representative combinations of concentrations at which the synergistic effect was particularly strong are shown by dots. Representative synergistic effects of combinations are also depicted (right panel) (CH0680, DAC 100 nM and TAK-243 33 nM; CH1277, DAC 33 nM and TAK-243 100 nM) (n = 3 for each group, biological replicates). c Schema of the PDX study. Treatment timing is depicted. d Absolute number of human CD45-positive cells in PB and their ratio before and after treatment in each group (n = 4 for each group, biological replicates). ***p < 0.001 by the Student’s t-test. Data are presented as mean ± SD. Source data are provided as a Source Data file.